Cargando…
EGFR-TKI原发性耐药的分子机制及其进展——附2例病例分析
Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutation...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348160/ https://www.ncbi.nlm.nih.gov/pubmed/30674394 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.01.10 |